SUBSCRIBE
SUBSCRIBE
Dan Samorodnitsky

Dan Samorodnitsky

News Editor

Dan Samorodnitsky is the news editor at BioSpace. He has a decade of experience covering biotech, genetics and medicine. Before coming to BioSpace he was an editor at Drug Discovery News and Massive Science, and his writing has appeared in outlets such as Quanta, STAT, GROW and many others. He is based in Minneapolis. You can reach him at dan.samorodnitsky@biospace.com.

Vector illustration representing kidney care, highlighting the importance of health and medical attention for these vital organs
Rare diseases
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
March 21, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
medical bottles isolated on blue background, drugs and
Mergers & acquisitions
Paratek Broadens Portfolio With OptiNose Buy Worth up to $330M
Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic treatment Nuzyra.
March 20, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
A businessman jumps over a cliff. Art collage.
Patents
Just How Steep Is the Drug Patent Cliff? Ask These Pharmas
With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that have taken the leap off the patent cliff.
March 19, 2025
 · 
5 min read
 · 
Dan Samorodnitsky
Hand shake icon on wooden cube block which connection with human icon for business deal and agreement concept.
Deals
Servier Nabs Solid Tumor Asset in up to $780M Deal With Black Diamond
The French pharma is getting Black Diamond’s de-prioritized molecule for non-small cell lung cancers with specific mutations whose development had been paused to save money.
March 19, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Podcasts
Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio
Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations without advisor input; Trump CDC nominee Dave Weldon pulled at last minute; and FDA decisions expected for Alnylam’s Amvuttra in ATTR-CM and Milestone’s etripamil in tachycardia.
March 19, 2025
 · 
2 min read
 · 
Heather McKenzie
Invest in best idea Investment and analysis money cash profits metaphor Flat tiny people and business concept for trading Economical wealth revenue visualized as growing on a tree vector illustration Field of Dreams
Gene editing
Arbor Raises $73.5M To Ride Out Gene Editing’s ‘Gartner Hype Cycle’
The gene therapy world is in turmoil, but Arbor, armed with more than $1 billion in partnerships and raises, is going forward.
March 18, 2025
 · 
4 min read
 · 
Dan Samorodnitsky
A big businessman hands over the key to the house. Art collage, hand with keys.
Mergers & acquisitions
Taiho Pharmaceutical Buys ADC Partner Araris for up to $1.1B Total
Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.
March 17, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Vector illustration of a bottle of wine and a glass of wine on a yellow background in retro style.
GLP-1
Altimmune To Test Investigational GLP-1–Based Obesity Drug for Alcohol Use Disorder
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related conditions.
March 14, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
piggy bank behind umbrella to cover and protect from downturn arrow. Protection or defensive stock in economy crisis
Mergers & acquisitions
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy
The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an attempt to disrupt a merger with Alumis.
March 13, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Podcasts
COVID Reflections, Novo’s Next-Gen Weight Loss Struggles, Another Depression Miss, More
BioSpace remembers COVID-19 five years after the pandemic was declared, Novo Nordisk’s CagriSema again misses expectations as the company joins a lawsuit filed by drug compounders against the FDA, Viking secures ample supply of its investigational obesity medication, J&J strikes out in depression, and Makary and Bhattacharya near confirmation.
March 12, 2025
 · 
1 min read
 · 
Heather McKenzie
Man with medical or hygienic mask standing over dead covid 19 or Corona virus raised their hand to win the Covic-19 or Coronavirus, At last mankind will win and survive over the virus concept
Editorial
The Shape of a Pandemic: Boom, Bust and Recover
As we reflect on five years of COVID-19, it’s clear that the impacts are still unfolding. The life sciences—and we as individuals—will never be the same again.
March 11, 2025
 · 
6 min read
 · 
Jef Akst
Tiny doctors examining heart health flat vector illustration. Cartoon medical specialists doing checkup of blood pressure, pulse rate and cholesterol. Cardiovascular disease and cardiology concept
Cardiovascular disease
Mineralys’ Hypertension Drug Drops Blood Pressure in Phase II/III, Setting Up Market Clash
Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in a pair of clinical trials.
March 10, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Novo Nordisk headquarters in Silicon Valley
Obesity
Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional clinical trials of its GLP-1 drugs in addiction beyond a Phase II trial testing semaglutide and two other drugs with alcohol use as a secondary endpoint.
March 7, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Speech Bubble Puzzle and Discussion
Patents
Merck’s Injectable Keytruda Plans Create Legal Dispute With Halozyme: WSJ
The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that convert intravenous drugs into injectable versions.
March 5, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Two human hands with a gesture of a handshake agreement and dollar banknotes with dollar signs on a colored background. Concept of business contract or agreement. Collage art
Cancer
BeiGene Gets Yet Another Label Expansion for PD-1 Drug Tevimbra
The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the drug in gastric and gastroesophageal cancers as BeiGene also pushes forward a pipeline of novel cancer therapies.
March 4, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Load More